Esri, the global leader in location intelligence, will debut thePower of Where Collectionat the 2026 Esri User Conference in July. The collection builds on the ideas introduced in The Power of Where: A Geographic Approach to the World's Greatest Challenges ,by Esri president Jack Dangermond, published in 2024. The new collection expands these foundational concepts into focused, real-world...

ExaGrid ®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (creating a tiered air gap), delayed deletes and immutability for ransomware recovery, announced today that MES Computing, a brand ofThe Channel Company, has...

Bars are major social and economic contributors to communities around the world, according to new research conducted by Oxford Economics. The study, commissioned by AB InBev, examined the economic and social impact of bars across five global markets — Brazil, Mexico...

Global Brand Supports Prince of Wales' Philanthropic Polo Event, Raising...

CRANBROOK, BC /ACCESS Newswire/ July 14, 2026 / Eagle Plains Resources Ltd. (TSXV:EPL)(OTCQB:EGPLF) ("EPL" or "Eagle Plains" or "the Company")andPacific Bay Minerals Corp. (TSXV:PBM)("Pacific Bay" or "PBM") are pleased to announce that further to their respective news releases dated April 27, 2026 the parties have entered into an option agreement (the "Agreement") dated July 7, 2026, pursuant to which Pacific Bay has been granted the exclusive right to acquire up...

STARTEEPO Invest (“STARTEEPO”), a Prague-based alternative investment fund focused on high-conviction public equity investments, today announced that it has increased its beneficial ownership position in Xerox Holdings Corporation (“Xerox” or the “Company”) to 8.8 million common shares, together with options on an additional 140,000 shares, as disclosed in an amended...

Preliminary Unaudited Q4 Revenue Expected to Exceed $1.0 Million, With More Than $750,000 in Unshipped...

Media OutReach...

Media OutReach...

Merck, a leading global science and technology company, today announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indicated in combination with encorafenib for patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) — both in first-line treatment in combination with FOLFOX (BREAKWATER...